Meeting
2023 ASCO Quality Care Symposium
Oral complications in patients with breast cancer treated with HER2-targeted therapies: A population-based cohort study across the United States.
Authors
Tina Yi Jin Hsieh
Beth Israel Deaconess Medical Center, Boston, MA
Tina Yi Jin Hsieh, Pin-Chia Huang, Herve Sroussi, Sheng-Yin Chen, Chuan Lu, Kevin Sheng-Kai Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 296)
DOI
10.1200/OP.2023.19.11_suppl.296
Abstract #
296
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study.
First Author: Jenna Bhimani
Poster
2021 ASCO Annual Meeting
Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.
First Author: Marietta Scott
Poster
2019 ASCO Annual Meeting
Prediction of biomarker status, diagnosis and outcome from histology slides using deep learning-based hypothesis free feature extraction.
First Author: Eldad Klaiman
Poster
2017 ASCO Annual Meeting
UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).
First Author: Ines Maria Vaz Duarte Luis